Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1996-02-16
2000-08-01
Chin, Christopher L.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
4241841, 4241851, 4241901, 4241921, 42419611, 42419711, 4242001, 4242011, 4242341, 4242421, A61K 39108, A61K 3900, A61K 3902, A61K 39295
Patent
active
060963212
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The present invention relates to the sub-unit of the CS31A protein capsule, referred to as the "ClpG protein", whose amino-acid sequence is modified by at least one heterologous peptide.
The invention also relates to the CS31A protein capsule that includes such a sub-unit, as well as the microorganisms that carry a CS31A protein capsule for which amino-acid sequence in the sub-unit is modified by at least one heterologous peptide.
The invention also relates to the procedures for obtaining such sub-units, to the CS31A capsules that contain them, and to microorganisms that carry these CS31A protein capsules, as well as to the use of these capsules in the preparation of vaccines, the production of peptides, and the preparation of immunological tests.
BACKGROUND OF THE INVENTION
The outer membrane of microorganisms includes various protein structures, such as flagella, pili, fimbriae, or protein capsules, which in particular endow the said microorganisms with properties of motion or attachment.
These structures include highly antigenic molecules that have made it possible to prepare, starting with the protein structure isolated from these microorganisms or from the microorganisms themselves, vaccines that correspond to the various types of antigens isolated in the microorganisms. Thus, the French patent application published under No. 2 466 251 proposes an anti-colibacillus animal vaccine that contains at least one antigen obtained from various strains of Escherichia coli.
Furthermore, these molecules constitute a comparable number of carrier proteins into which foreign epitopes can be introduced that endow the said proteins with a new antigenic nature, whose immunogenicity allows the said proteins to be used as vaccines. Thus, the European patent application published under No. 264 150 describes microorganisms whose outer membrane carries pili whose composition has been modified by a change in the protein sequence of the sub-unit.
Membrane structures such as pili, fimbriae, or protein capsules appear to be more advantageous in the field of vaccination than outer-membrane proteins. In fact, for pili, all of the structural protein is located outside the cell; certain polypeptide regions are present only at the cell surface; and accessibility to these proteins risks being impeded by the lipopolysaccharide and the capsular envelopes. Furthermore, the sub-units of the fimbriae or of the protein capsules are present at the bacterial surface in much greater numbers than the outer-membrane proteins.
Furthermore, the purification of a membrane protein is more difficult than the purification of proteins that are entirely outside the microorganisms, such as pili or fimbriae.
The nature of the microorganisms involved in the invention depends solely on their ability to produce the CS31A protein capsule. Specifically, it involves bacteria in the family of Enterobacteriaceae that belong to the Escherichia coli and Klebsiella pneumoniae species.
Many studies have been made of the pili of E. coli, and, more specifically, the K88 and K99 fimbrial sub-units have been amply described.
More recent studies have revealed, in a wild strain of E. coli designated as "31A+" in the French patent application published under No. 2 466 251, a protein structure designated as "CS31A". The operon that governs the biogenesis of this structure has been cloned in a host organism, and the gene that codes for the CS31A sub-unit, referred to as "Clpg", has been located, characterized, and sequenced. (See C. Martin, C. Boeuf, and F. Bousquet, in Microbial Pathogenesis, Vol. 10 (1991), pp. 429-442; J. P. Girardeau, Y. Bertin, C. Martin, M. DerVartanian, and C. Boeuf, in Journal of Bacteriology, Vol. 173, No. 23 (December 1991), pp. 7673-7983; and M. J. Korth, R. A. Schneider, and S. L. Moseley, in Infection and Immunity, Vol. 59, No. 7 (July 1991), pp. 2333-2340).
The CS31A structure is a protein capsule that is less organized and more flexible than the flagella and fimbriae, which are more organized and rigid. Consequently
REFERENCES:
Hedegaard et al, J. Cell Biochem Suppl 12 B, p. 41 (1988).
Girardeau et al. Journal of Bacteriology 173(23):7673-7683, 1991.
Martin et al. Microbial Pathogenesis 10:429-442, 1991.
Bakker et al. Microbial Pathogenesis 8:343-352, 1990.
Kohli et al. Journal of General Virology 73:907-914, 1992.
Delmas et al. Journal of General Virology 71:1313-1323, 1990.
Bousquet Fran.cedilla.ois
Der Vartanian Maurice
Girardeau Jean-Pierre
Martin Christine
Mechin Marie-Claire
Chin Christopher L.
Institut National de la Recherche Agronomique-INRA
Ryan V.
LandOfFree
ClpG subunit of CS31A protein capsule containing heterologous pe does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ClpG subunit of CS31A protein capsule containing heterologous pe, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ClpG subunit of CS31A protein capsule containing heterologous pe will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-661078